Cabiralizumab

• CAT Number: I042444
• CAS Number: 1613144-80-1
• Purity: ≥95%

Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research[1][2].

Reference

[1]. Weiss SA, et al. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27(17):4757-4767.
 [Content Brief]

[2]. Peyraud F, et al. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19(11):70.
 [Content Brief]